Review on intermediate filaments of the nervous system and their pathological alterations

AbstractIntermediate filaments (IFs) of the nervous system, including neurofilaments, α-internexin, glial fibrillary acidic protein, synemin, nestin, peripherin and vimentin, are finely expressed following elaborated cell, tissue and developmental specific patterns. A common characteristic of several neurodegenerative diseases is the abnormal accumulation of neuronal IFs in cell bodies or along the axon, often associated with impairment of the axonal transport and degeneration of neurons. In this review, we also present several perturbations of IF metabolism and organization associated with neurodegenerative disorders. Such modifications could represent strong markers of neuronal damages. Moreover, recent data suggest that IFs represent potential biomarkers to determine the disease progression or the differential stages of a neuronal disorder. Finally, recent investigations on IF expression and function in cancer provide evidence that they may be useful as markers, or targets of brain tumours, especially high-grade glioma. A better knowledge of the molecular mechanisms of IF alterations, combined to neuroimaging, is essential to improve diagnosis and therapeutic strategies of such neurodegenerative diseases and glioma.

[1]  Jeffrey A. Cohen,et al.  Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons , 1993, The Journal of comparative neurology.

[2]  F. Dasí,et al.  Loss of heterozygosity at 1p-19q induces a global change in oligodendroglial tumor gene expression , 2009, Journal of Neuro-Oncology.

[3]  Webster K. Cavenee,et al.  Erratum: The 2007 WHO classification of tumours of the central nervous system (Acta Neuropathol (2007) vol. 114 (97-109)) , 2007 .

[4]  J. Julien,et al.  Normal role of the low‐molecular‐weight neurofilament protein in mitochondrial dynamics and disruption in Charcot‐Marie‐Tooth disease , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  R. Hoffman Nestin-driven green fluorescent protein as an imaging marker for nascent blood vessels in mouse models of cancer. , 2011, Methods in molecular biology.

[6]  E. Lane,et al.  The Human Intermediate Filament Database: comprehensive information on a gene family involved in many human diseases , 2008, Human mutation.

[7]  C. Bettegowda,et al.  Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas , 2012, Journal of Neuro-Oncology.

[8]  I. Pommepuy,et al.  Alpha-internexin expression in gliomas: relationship with histological type and 1p, 19q, 10p and 10q status , 2011, Journal of Clinical Pathology.

[9]  G. Gabbiani,et al.  Intermediate filament protein synemin is present in human reactive and malignant astrocytes and associates with ruffled membranes in astrocytoma cells , 2005, Glia.

[10]  R A Crowther,et al.  alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[11]  H. Armah Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile , 2010 .

[12]  R. Perrot,et al.  Neuronal intermediate filaments and neurodegenerative disorders , 2009, Brain Research Bulletin.

[13]  L. Rosengren,et al.  Serum levels of glial fibrillary acidic protein correlate to tumour volume of high‐grade gliomas , 2007, Acta neurologica Scandinavica.

[14]  D. Řípová,et al.  Patients with Alzheimer disease have elevated intrathecal synthesis of antibodies against tau protein and heavy neurofilament , 2012, Journal of Neuroimmunology.

[15]  R. Liem Neuronal intermediate filaments. , 1990, Current opinion in cell biology.

[16]  B. Helfand,et al.  Rapid transport of neural intermediate filament protein , 2003, Journal of Cell Science.

[17]  B. Bergamasco,et al.  Proteome analysis of human substantia nigra in Parkinson's disease , 2004, Proteomics.

[18]  Haibo Chen,et al.  Correlational study of the serum levels of the glial fibrillary acidic protein and neurofilament proteins in Parkinson's disease patients , 2012, Clinical Neurology and Neurosurgery.

[19]  A. Hays,et al.  Peripherin and Neurofilament Protein Coexist in Spinal Spheroids of Motor Neuron Disease , 1992, Journal of neuropathology and experimental neurology.

[20]  M. Strong,et al.  Quantitative phosphoproteomic analysis of neuronal intermediate filament proteins (NF‐M/H) in Alzheimer's disease by iTRAQ , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  K. Hoang-Xuan,et al.  α-Internexin expression identifies 1p19q codeleted gliomas , 2009, Neurology.

[22]  W G Alvord,et al.  Familial Amyotrophic Lateral Sclerosis, 1850-1989: A Statistical Analysis of the World Literature , 1991, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[23]  L. Rosengren,et al.  Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS , 2003, Neurology.

[24]  H. Steinmetz,et al.  Serum GFAP is a diagnostic marker for glioblastoma multiforme. , 2007, Brain : a journal of neurology.

[25]  R. Bjerkvig,et al.  DNA repair and cancer stem-like cells--potential partners in glioma drug resistance? , 2008, Cancer treatment reviews.

[26]  G. Perry,et al.  Phosphorylation of Neurofilaments Is Altered in Amyotrophic Lateral Sclerosis , 1988, Journal of neuropathology and experimental neurology.

[27]  O. Kalita,et al.  Analysis of VEGF, Flt-1, Flk-1, nestin and MMP-9 in relation to astrocytoma pathogenesis and progression. , 2009, Neoplasma.

[28]  勇人 伊古田 Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology , 2007 .

[29]  J. Julien,et al.  Normal dendritic arborization in spinal motoneurons requires neurofilament subunit L , 2002, The Journal of comparative neurology.

[30]  Arie Perry,et al.  Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. , 2007, Archives of pathology & laboratory medicine.

[31]  D. Rodriguez,et al.  Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease , 2001, Nature Genetics.

[32]  S. Züchner,et al.  Mechanisms of Disease: a molecular genetic update on hereditary axonal neuropathies , 2006, Nature Clinical Practice Neurology.

[33]  Kimberly L. Walker,et al.  Loss of Neurofilaments Alters Axonal Growth Dynamics , 2001, The Journal of Neuroscience.

[34]  T. Matsushige,et al.  Serum neurofilament concentrations in children with prolonged febrile seizures , 2012, Journal of the Neurological Sciences.

[35]  N. Hashimoto,et al.  Gene Expression-Based Molecular Diagnostic System for Malignant Gliomas Is Superior to Histological Diagnosis , 2007, Clinical Cancer Research.

[36]  R. Lindberg,et al.  Neurofilament heavy chain and heat shock protein 70 as markers of seizure‐related brain injury , 2012, Epilepsia.

[37]  H. Wiśniewski,et al.  An Antigenic Profile of Lewy Bodies: Immunocytochemical Indication for Protein Phosphorylation and Ubiquitination , 1989, Journal of neuropathology and experimental neurology.

[38]  A. Messing,et al.  GFAP expression as an indicator of disease severity in mouse models of Alexander disease , 2013, ASN neuro.

[39]  E. Shaw,et al.  A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. , 2006, Cancer research.

[40]  J. Kassubek,et al.  Neurofilament heavy‐chain NfHSMI35 in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes , 2006, Movement disorders : official journal of the Movement Disorder Society.

[41]  Y. Kim,et al.  Degeneration and transdifferentiation of human lens epithelial cells in nuclear and anterior polar cataracts. , 1999, Journal of cataract and refractive surgery.

[42]  I. Nakano,et al.  Brain Tumor Stem Cells , 2006, Pediatric Research.

[43]  J. Schiefer,et al.  Neurofilament light chain as an early and sensitive predictor of long-term neurological outcome in patients after cardiac arrest. , 2013, International journal of cardiology.

[44]  C. Polman,et al.  Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[45]  J. Žůrek,et al.  Hyperphosphorylated neurofilament NF-H as a predictor of mortality after brain injury in children , 2011, Brain injury.

[46]  M. Perng,et al.  Alexander disease causing mutations in the C-terminal domain of GFAP are deleterious both to assembly and network formation with the potential to both activate caspase 3 and decrease cell viability. , 2011, Experimental cell research.

[47]  P. Janmey,et al.  Bidirectional translocation of neurofilaments along microtubules mediated in part by dynein/dynactin. , 2000, Molecular biology of the cell.

[48]  A. Ludolph,et al.  Axonal damage markers in cerebrospinal fluid are increased in ALS , 2006, Neurology.

[49]  H. Zetterberg,et al.  Light subunit of neurofilament triplet protein in the cerebrospinal fluid after subthalamic nucleus stimulation for Parkinson’s disease , 2011, Acta neurologica Scandinavica.

[50]  C. Wikkelsø,et al.  Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF , 1996, Journal of neurochemistry.

[51]  M. Faiz,et al.  Synemin is expressed in reactive astrocytes and Rosenthal fibers in Alexander disease , 2014, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[52]  W. F. Abdo,et al.  CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease , 2007, Neurobiology of Aging.

[53]  S. Beck,et al.  Cell surface Nestin is a biomarker for glioma stem cells. , 2013, Biochemical and biophysical research communications.

[54]  Gerry Shaw,et al.  Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[55]  O. Skalli,et al.  Intermediate filament protein synemin contributes to the migratory properties of astrocytoma cells by influencing the dynamics of the actin cytoskeleton , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[56]  P. Mulvihill,et al.  Filaments of Lewy bodies contain insoluble cytoskeletal elements. , 1992, The American journal of pathology.

[57]  O. Evgrafov,et al.  A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. , 2000, American journal of human genetics.

[58]  R. Liem,et al.  Mutations in the neurofilament light gene linked to Charcot‐Marie‐Tooth disease cause defects in transport , 2005, Journal of neurochemistry.

[59]  A. Orr,et al.  Synemin promotes AKT-dependent glioblastoma cell proliferation by antagonizing PP2A , 2012, Molecular biology of the cell.

[60]  Meng Yang,et al.  Nestin-linked green fluorescent protein transgenic nude mouse for imaging human tumor angiogenesis. , 2005, Cancer research.

[61]  L. Rosengren,et al.  Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis , 2010, Journal of Neurology.

[62]  E. Dahl,et al.  Intermediate filament dynamics and breast cancer: Aberrant promoter methylation of the Synemin gene is associated with early tumor relapse , 2010, Oncogene.

[63]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[64]  P. Wong,et al.  Pathogenesis of two axonopathies does not require axonal neurofilaments , 1998, Nature.

[65]  K. Blennow,et al.  Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. , 2012, Archives of neurology.

[66]  M. Reilly NEFL‐related Charcot–Marie–Tooth disease: An unraveling story , 2009, Annals of neurology.

[67]  M. Mann,et al.  Integrated analysis of the cerebrospinal fluid peptidome and proteome. , 2008, Journal of proteome research.

[68]  G. Giovannoni,et al.  A specific ELISA for measuring neurofilament heavy chain phosphoforms. , 2003, Journal of immunological methods.

[69]  A. Peterson,et al.  Neurofilament-deficient axons and perikaryal aggregates in viable transgenic mice expressing a neurofilament-β-galactosidase fusion protein , 1994, Neuron.

[70]  M N Rossor,et al.  A Systematic Review and Meta-Analysis of CSF Neurofilament Protein Levels as Biomarkers in Dementia , 2007, Neurodegenerative Diseases.

[71]  H. Ishikawa,et al.  MITOSIS AND INTERMEDIATE-SIZED FILAMENTS IN DEVELOPING SKELETAL MUSCLE , 1968, The Journal of cell biology.

[72]  G. Logroscino,et al.  Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression , 2012, European journal of neurology.

[73]  V. Tung,et al.  Antagonistic Roles of Neurofilament Subunits NF-H and NF-M Against NF-L in Shaping Dendritic Arborization in Spinal Motor Neurons , 1998, The Journal of cell biology.

[74]  John Hardy,et al.  A Hundred Years of Alzheimer's Disease Research , 2006, Neuron.

[75]  Zhigang Xie Brain Tumor Stem Cells , 2009, Neurochemical Research.

[76]  H. Wiśniewski,et al.  Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[77]  L. Rosengren,et al.  Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis , 1998, Journal of neurology, neurosurgery, and psychiatry.

[78]  D. Nam,et al.  Identification of a peptide that interacts with Nestin protein expressed in brain cancer stem cells. , 2011, Biomaterials.

[79]  Tomokatsu Yoshida,et al.  Clinical aspects and pathology of Alexander disease, and morphological and functional alteration of astrocytes induced by GFAP mutation , 2012, Neuropathology : official journal of the Japanese Society of Neuropathology.

[80]  Gerry Shaw,et al.  Hyperphosphorylated neurofilament NF-H is a serum biomarker of axonal injury. , 2005, Biochemical and biophysical research communications.

[81]  C. Shaw,et al.  Charcot-Marie-Tooth disease neurofilament mutations disrupt neurofilament assembly and axonal transport. , 2002, Human molecular genetics.

[82]  F. Caire,et al.  1p19q LOH patterns and expression of p53 and Olig2 in gliomas: relation with histological types and prognosis , 2010, Modern Pathology.

[83]  S. Bhattacharya,et al.  Dominant cataract formation in association with a vimentin assembly disrupting mutation. , 2009, Human molecular genetics.

[84]  B. Kalmar,et al.  Plasma Neurofilament Heavy Chain Levels Correlate to Markers of Late Stage Disease Progression and Treatment Response in SOD1G93A Mice that Model ALS , 2012, PloS one.

[85]  P. Cochard,et al.  Initial expression of neurofilaments and vimentin in the central and peripheral nervous system of the mouse embryo in vivo , 1984, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[86]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[87]  M. Sharief,et al.  Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability , 2002, Journal of Neuroimmunology.

[88]  R. McKay,et al.  CNS stem cells express a new class of intermediate filament protein , 1990, Cell.

[89]  K. Aldape,et al.  Anaplastic Oligodendroglial Tumors: Refining the Correlation among Histopathology, 1p 19q Deletion and Clinical Outcome in Intergroup Radiation Therapy Oncology Group Trial 9402 , 2008, Brain pathology.

[90]  I. Grundke‐Iqbal,et al.  Hyperphosphorylation and accumulation of neurofilament proteins in Alzheimer disease brain and in okadaic acid‐treated SY5Y cells , 2001, FEBS letters.

[91]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[92]  V. Meininger,et al.  A Frameshift Deletion in Peripherin Gene Associated with Amyotrophic Lateral Sclerosis* , 2004, Journal of Biological Chemistry.

[93]  V. Meininger,et al.  Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. , 1994, Human molecular genetics.

[94]  T B Shea,et al.  Kinesin-mediated transport of neurofilament protein oligomers in growing axons. , 1999, Journal of cell science.

[95]  R. Nixon,et al.  Dynamics of neuronal intermediate filaments: a developmental perspective. , 1992, Cell motility and the cytoskeleton.

[96]  E. Perry,et al.  Neurogenic abnormalities in Alzheimer's disease differ between stages of neurogenesis and are partly related to cholinergic pathology , 2012, Neurobiology of Disease.

[97]  M. Omary,et al.  Intermediate filament proteins and their associated diseases. , 2004, The New England journal of medicine.

[98]  I. Grundke‐Iqbal,et al.  Regulation between O‐GlcNAcylation and phosphorylation of neurofilament‐M and their dysregulation in Alzheimer disease , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[99]  Yoav Ben-Shlomo,et al.  The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. , 2002, Brain : a journal of neurology.

[100]  K. Hoang-Xuan,et al.  Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas. , 2011, European journal of cancer.

[101]  Y. Itoyama,et al.  Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker , 2009, Journal of Neurology, Neurosurgery, and Psychiatry.